Teva’s quest to expand approval of its respiratory drug Cinquair/Cinqaero with a new mode of delivery has hit a snag, after two late-stage studies failed to hit their targets.
The European Commission has issued a green light for Teva’s Cinqaero in the 28 countries of the European Union in addition to Norway, Liechtenstein and Iceland.